Advertisement

Topics

STAT Plus: To go after drug-resistant gonorrhea, partners put a new spin on drug development

04:30 EDT 31 Jul 2017 | STAT

Drug-resistant gonorrhea is the target of a new antibiotic being developed by Entasis, an antibiotics-focused spin-off from pharma giant AstraZeneca.

Original Article: STAT Plus: To go after drug-resistant gonorrhea, partners put a new spin on drug development

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: To go after drug-resistant gonorrhea, partners put a new spin on drug development"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...